Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0016382 (flushing)
 6,387 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Org OD 14, a synthetic steroid with an unusual endocrine profile (weak progestational, weak estrogenic, very weak androgenic, and clear anabolic activity), was tested in a double-blind trial of 100 postmenopausal women to assess its efficacy as treatment for osteoporosis associated with menopause. This agent should reduce incidence of postmenopausal vascular disease and be free of the side effects of prolonged estrogen treatment (endometrial hyperplasia and carcinoma). Of the 100 women studied, 63 completed 2 years of treatment (33 on Org OD 14, and 30 on placebo). 2.5 mg/day was administered, and this dose successfully prevented bone loss over 2 years; on the other hand, a significant reduction in bone mineral content occurred in those women taking placebo. The difference was statistically significant (P .01). At this dosage, Org OD 14 also significantly reduced the severity of menopausal complaints, including flushing and sweating. Vabra aspiration curettage in 20 cases 6-18 months after starting active treatment showed no evidence of endometial hyperlasia, although weak proliferation of the endometrium was apparent in 3 cases. Org OD 14 does not seem to produce extensive endometrial stimulation; therefore, the potential of this agent in osteoporosis and other postclimacteric complaints warrants further investigation.
 ...
PMID:Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. 699 27

Menopause and the accompanying reduction in estrogen production may cause a number of symptoms in women which include hot flushes, sweating, mood and sleep disturbances, fatigue and urogenital dysfunction. The effectiveness of estrogen-based hormone replacement therapy (HRT) in ameliorating these symptoms, and in preventing long term sequelae such as osteoporosis, is well established. Comparative trials indicate that oral conjugated estrogens 0.625mg, oral ethinyl estradiol 0.02mg and transdermal estradiol 0.05mg have equivalent efficacy in relief of mild to moderate menopausal symptoms and prevention of bone mineral loss. Concomitant progestogen therapy is usually prescribed for women with intact uteri to protect against endometrial hyperplasia and carcinoma. The addition of progestogen maintains and may even enhance the bone-conserving effects of estrogen, and continuous regimens appear to reduce the incidence of irregular menses. Adverse reactions are predominantly local skin irritation with transdermal preparations (14% of patients) and systemic effects common to most forms of HRT including breast tenderness, flushing, headache and irregular bleeding, occurring in less than or equal to 2% of patients. Data concerning the effect of HRT on quality of life are limited, but most analyses have assigned utility values of 0.99 for mild and 0.95 for severe menopausal symptoms. However, recent clinical data suggest that these utility values may underestimate the impact of menopausal symptoms on quality of life. The cost benefit and cost effectiveness of HRT in the treatment of menopausal symptoms have not been fully researched, although preliminary results suggest that conjugated estrogens and transdermal estradiol compare well with alternative therapies such as veralipride and Chinese medicines. A Swedish study using a prevalence-based approach estimated that estriol treatment in all women with urinary incontinence aged greater than or equal to 65 years resulted in monetary savings compared with treating 20% of women. Cost-utility data indicated that the change in quality-adjusted life years (QALYs) with HRT was always positive, but the degree of change was determined by the baseline assumptions. Estimated changes in QALYs with HRT ranged from 0.006 for 5 years of treatment with unopposed estrogen in women with intact uteri, to 0.5 for 10 years of the same treatment in women with severe menopausal symptoms following hysterectomy. Compliance with HRT is suboptimal as 5 to 50% of women withdraw from therapy, thereby increasing costs per year of life saved.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Hormone replacement therapy: I. A pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen deficiency. 1014 33

The purpose of this study was to determine fertilization and karyotypes of embryos after interstrain insemination and survival of embryos after reciprocal transfers between the National Institutes of Health SLA miniature pig and standard crossbred pig. Recovery of viable embryos indicated fertilization rates were not different in the two strains. Karyotypes of cells from embryos of both strains had the same chromosome number. The wide variation (within animal) in developmental stages of embryos recovered from the SLA minipig suggests the possibility of a prolonged ovulation interval, or a super imposed recruitment of a second set of follicles ovulating a few hours later. Cystic endometrial hyperplasia in the SLA minipig reduced the number of embryos recovered due to mechanical blockage of the uterine horns, thus preventing adequate flushing. SLA minipig recipients with no morphological evidence of cystic endometrial hyperplasia have a similar pregnancy rate to the standard pig. Cystic endometrial hyperplasia may contribute to reduced reproductive efficiency of the SLA minipig as a result of a detrimental effect on early embryo development and/or implantation.
 ...
PMID:Interstrain inseminations and embryo transfers between the SLA miniature pig and standard crossbred pig. 1672 51